Bristol-Myers Squibb Co. (BMY)

50.07
NYSE : Health Technology
Prev Close 49.86
Day Low/High 49.66 / 50.53
52 Wk Low/High 42.48 / 63.69
Avg Volume 12.54M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 81.56B
EPS 3.00
P/E Ratio 13.09
Div & Yield 1.64 (3.28%)
Bristol-Myers Squibb Is Set to Emerge From a Basing Pattern

Bristol-Myers Squibb Is Set to Emerge From a Basing Pattern

TheStreet's quants like the stock. What do the charts say?

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

The Market Has Fury for a Suitor Scorned

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

An Avalanche and Build Up of Global Debt Combined With Slowing Global Economic Growth Are a Toxic Cocktail for Investors

* Ignore slowing global economic growth at your own risk * Global debt will continue to serve as a governor to growth * Global debt has not been supported by growth in the global economy * Like the Potemkin Village, global debt growth has created an...

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Jim Cramer: 7 Sectors You Can Buy as the Trade War Continues

Jim Cramer: 7 Sectors You Can Buy as the Trade War Continues

These stocks and sectors are safe havens, and may even be opportunities.

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

Jim Cramer: Add 'Better Than Feared' to Your Investing Lexicon

Jim Cramer: Add 'Better Than Feared' to Your Investing Lexicon

Here's the only way to explain why stocks jump like mad if the companies underneath them only perform slightly better than the analysts worried they would.

High Flyers and Low Flyers

Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...

SOX It to Me, Military Mischief in Asia, and Awaiting Amazon: Market Recon

SOX It to Me, Military Mischief in Asia, and Awaiting Amazon: Market Recon

And as the semiconductor sector continues to shine, Brooks Automation is a name to keep in mind.

Jim Cramer: Big Tech in Washington Will Mean an EPS Hit

Jim Cramer: Big Tech in Washington Will Mean an EPS Hit

Breaking down the impact on Facebook, Alphabet and Amazon of congressional hearings.

Watch These 4 Japanese Drugmakers With Big Coming Events

Watch These 4 Japanese Drugmakers With Big Coming Events

Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Let's check out the charts of BMY.

IPO Gives Chinese Couple a 'Hansoh' Sum

IPO Gives Chinese Couple a 'Hansoh' Sum

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Jim Cramer: What Do Trump's Whims Per Share Look Like?

Jim Cramer: What Do Trump's Whims Per Share Look Like?

What happened to the business president? I think what happened is that the polls are showing that whatever the president is doing is working.

Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only

Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only

BMY is not 'out of the woods' yet, but aggressive traders could probe the long side here.

Jim Cramer: It Isn't a Slowdown That I Fear, It's a Tweet

Jim Cramer: It Isn't a Slowdown That I Fear, It's a Tweet

This is the first time I can ever recall when a president is so attuned to the market that he will bend to its wishes.

Jim Cramer: What to Buy and What to Avoid on Trump's Latest China Tweet

Jim Cramer: What to Buy and What to Avoid on Trump's Latest China Tweet

As usual, the stocks that bounce back first are the tech stocks with little Chinese exposure and the consumer packaged goods that just demonstrated good numbers.